AnaptysBio, Inc. (ANAB) AI Stock Analysis

AnaptysBio, Inc., based in San Diego, California, is a clinical-stage biotechnology firm specializing in the development of therapeutic product candidates aimed at treating inflammation and immuno-oncology conditions. Its pipeline includes Imsidolimab, an antibody targeting the interleukin-36 receptor for dermatological inflammatory diseases, Rosnilimab, an anti-PD-1 agonist antibody designed to suppress T-cell driven inflammatory diseases, and ANB032, which targets BTLA modulation for inflammatory conditions. AnaptysBio advances its antibody programs through research and development collaborations with major pharmaceutical companies, including GlaxoSmithKline and Bristol-Myers Squibb.

AnaptysBio's revenue expanded at a 5-year CAGR of 25.6% from FY2020 to FY2025. Annual revenue grew from $10.3M in FY2022 to $91.3M in FY2024 and reached $234.6M in FY2025. Operating margin improved from -1119.4% in FY2022 to 20.4% in FY2025, while gross margin reached 99.0%. Net loss narrowed from -$163.6M in FY2023 to -$13.2M in FY2025, corresponding to an EPS of -$0.52. For the trailing twelve months ended June 30, 2026, revenue stood at $106.1M with an operating margin of 53.4% and an EPS of -$0.96. In the latest quarter, quarterly revenue grew 23.5% year over year.

As of June 30, 2026, AnaptysBio held $164.1M in cash and short-term investments against total debt of $269.6M, resulting in net debt of $105.4M. Shareholders' equity was $10.6M, leading to a debt-to-equity ratio of 25.47, while the current ratio stood at 5.61. Operating cash flow turned positive in FY2025 at $19.7M, alongside free cash flow of $19.6M. Capital expenditures in FY2025 were $87,000, and the company allocated $68.6M to share buybacks.

At $46.61 per share, AnaptysBio has a market capitalization of $1.39B and an enterprise value of $1.37B. The stock trades at a forward P/E of 21.0x, above the 17.3x median of its US-listed Healthcare peers. Its EV/EBITDA multiple of 23.4x also exceeds the peer median of 12.0x, while its price-to-sales ratio is 13.1x compared to the peer median of 4.1x. Over the past year, ANAB gained 103.2%, outperforming the S&P 500's return of 16.8%, and delivered a 5-year return of 143.9% versus 83.0% for the index.

Wall Street analysts hold 5 Strong Buy and 3 Buy ratings on ANAB, with no Hold or Sell recommendations. The mean price target is $87.25, representing an upside of 87.2% from the last close of $46.61. For the current fiscal year ending December 31, 2026, analysts estimate EPS of $4.35 on revenue of $101.1M. For the next fiscal year, consensus models call for EPS of $5.07 and revenue of $171.3M. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of AnaptysBio, Inc. (ANAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ANAB income statement, ANAB balance sheet, ANAB key metrics, ANAB analyst forecast, ANAB chart. See the ANAB stock overview for the latest quote and news.